查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1772229

全球胃癌診斷市場：市場規模、佔有率、趨勢分析（按產品、疾病類型、最終用途和地區）、細分市場預測（2025-2033）

Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric lymphoma), By End Use, By Region And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

胃癌診斷市場概況

2024 年全球胃癌診斷市場規模估計為 11.8 億美元，預計到 2033 年將達到 22.2 億美元，2025 年至 2033 年的複合年成長率為 7.43%。胃癌發病率的上升、對早期檢測和篩檢計劃的日益重視以及對個人化醫療的需求不斷成長，正在推動市場成長。

胃癌是全球第五大常見癌症，其發生率的不斷上升推動了對先進診斷工具的需求，並凸顯了早期發現和改善患者預後的迫切需求。根據美國國家癌症研究所 (NIH) 的數據，預計到 2025 年，全球將新增約 30,300 例胃癌病例，並導致約 10,780 例胃癌死亡。

幽門螺旋桿菌感染、吸菸、高鹽飲食和老齡化等因素都會加重胃癌的發病負擔。胃癌死亡率隨年齡增加而上升。 2019年和2023年的年齡調整死亡率均為每10萬人每年2.7例（男性和女性）。下圖顯示了2019年至2022年各年齡層胃癌新病例的比例。

胃癌是全球癌症相關死亡的主要原因之一，因此對早期精準診斷工具的需求日益成長。醫療保健系統越來越重視篩檢項目和早期檢測，這推動了對內視鏡檢查、切片檢查、影像技術和分子診斷的需求，顯著擴大了傳統和先進診斷解決方案的市場。

市場成長的另一個驅動力是世界各國政府和醫療機構正在實施的篩檢計畫的擴展，以便在早期、更可治療的階段發現高風險族群中的胃癌。例如，2025 年 4 月，美國國立衛生研究院 (NIH) 將在五年內向研究人員提供 260 萬美元的資助，以領導一個由研究人員、臨床醫生和電腦科學家組成的國家團隊，評估在美國進行胃癌篩檢的可行性。日本和韓國等國家已經建立了包括內視鏡檢查在內的全國性篩檢舉措，這已被證明可有效降低死亡率。隨著類似計劃擴展到其他地區，對準確且高效的診斷工具的需求正在成長。這種向預防腫瘤學和早期檢測的轉變是胃癌診斷行業發展的強大驅動力，尤其是在公共醫療系統尋求降低長期治療成本的情況下。

個人化醫療的轉變正在對胃癌診斷產業產生重大影響。基於生物標記的檢測和基因組分析使臨床醫生能夠根據患者的個別情況制定個人化治療方案，從而改善治療效果。這種精準方法依賴先進的診斷工具，例如次世代定序(NGS)、免疫組織化學和伴隨診斷。隨著標靶治療的日益普及，對用於識別胃癌中 HER2、PD-L1、MSI 和其他生物標記的分子診斷的需求也日益成長。個人化醫療可以提高存活率，並提高治療的成本效益，從而鼓勵醫療保健提供者和付款方採用更先進的診斷平台。例如，在轉移性膽道癌中，年輕患者的預後往往比老年患者更好，因為他們的腫瘤更有可能存在可操作的基因變異，而這些變異正是個人化治療的候選對象。

生物標記能夠在早期階段檢測出與癌症發展相關的分子和基因變化，這對於改善患者預後至關重要。生物標記，尤其是在血液和其他體液中發現的生物標記物，與內視鏡檢查和切片檢查相比，可以提供非侵入性或微創性的檢查選擇，並減少患者的不適感。它們還能即時監測病情進展和療效，促進個人化醫療。此外，生物標記有助於克服影像診斷的局限性，例如解析度低和對操作者的依賴性，並以更高的靈敏度和特異性區分良性和惡性病變。因此，下文列出了生物標記在胃癌診斷中的新興趨勢。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 胃癌診斷市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 胃癌診斷市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章胃癌診斷市場：按產品分類的估計和趨勢分析

  • 各產品市場佔有率（2024 年及 2033 年）
  • 細分儀表板
  • 胃癌診斷市場：按產品分類的波動分析
  • 胃癌診斷市場規模及產品趨勢分析（2021-2033）
  • 胃癌診斷市場：收益估計與預測（2021-2033）
  • 試劑和耗材
  • 裝置

第5章胃癌診斷市場：依疾病類型估計與趨勢分析

  • 按疾病類型分類的市場佔有率（2024 年和 2033 年）
  • 細分儀表板
  • 胃癌診斷市場：依疾病類型波動分析
  • 市場規模預測與趨勢分析（2021-2033）
  • 腺癌
  • 胃淋巴瘤
  • 其他

第6章胃癌診斷市場：依最終用途的估計和趨勢分析

  • 按最終用途分類的市場佔有率（2024 年和 2033 年）
  • 細分儀表板
  • 胃癌診斷市場：依最終用途分類的差異分析
  • 市場規模預測與趨勢分析（2021-2033）
  • 醫院
  • 診斷實驗室
  • 診斷影像

第7章胃癌診斷市場：按地區估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2033 年）
  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 市場規模預測與趨勢分析（2021-2033）
  • 北美洲
    • 北美：SWOT分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • MEA：SWOT分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要企業近期趨勢及影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析（2024年）
    • MiRXES Pte Ltd.
    • Agilent Technologies Inc
    • Endofotonics Pte Ltd
    • Bio-Rad Laboratories, Inc
    • Hipro Biotechnology Co., Ltd
    • Exact Sciences Corporation
    • QIAGEN
    • Fulgent Genetics.
    • F. Hoffmann-La Roche Ltd
    • Abbott
Product Code: GVR-4-68040-648-2

Gastric Cancer Diagnostics Market Summary

The global gastric cancer diagnostics market was estimated at USD 1.18 billion in 2024 and is projected to reach USD 2.22 billion by 2033, growing at a CAGR of 7.43% from 2025 to 2033. The market is growing, driven by the rising incidence of gastric cancer, growing emphasis on early detection and screening programs, and escalating demand for personalized medicines.

Gastric cancer ranks as the 5th most common cancer worldwide, and its rising incidence drives the demand for advanced diagnostic tools, highlighting the urgent need for early detection and improved patient outcomes. According to the National Cancer Institute (NIH), in 2025, it is projected that there will be approximately 30,300 new stomach cancer cases, with about 10,780 deaths expected from the disease

Some of the factors, such as Helicobacter pylori infection, smoking, high-salt diets, and aging, are contributing to a higher disease burden. The mortality rate for gastric cancer rises as people get older. In 2019 and 2023, the age-adjusted death rate for both men and women was 2.7 per 100,000 individuals annually. The chart below illustrates the percentage of new cases (%) by age group of gastric cancer for the period 2019-2022

Gastric cancer, being one of the leading causes of cancer-related deaths worldwide, has led to a rising demand for its early, accurate diagnostic tools. Healthcare systems are placing greater emphasis on screening programs and early detection, which drives the need for endoscopy, biopsy, imaging technologies, and molecular diagnostics, significantly expanding the market for both conventional and advanced diagnostic solutions.

Another factor for market growth is growing screening programs that the governments and healthcare organizations worldwide are implementing to detect gastric cancer in high-risk populations at earlier, more treatable stages. For instance in April, 2025, National Institutes of Health (NIH) has awarded a researcher USD 2.6 million over five years to lead a national team of researchers, clinicians, and computer scientists in evaluating the feasibility of gastric cancer screening in the U.S. Early detection significantly improves survival rates, prompting increased investments in diagnostic infrastructure. Countries like Japan and South Korea have established nationwide screening initiatives that include endoscopic examinations, which have proven effective in reducing mortality. As similar programs expand to other regions, the need for accurate and efficient diagnostic tools grows. This push toward preventive oncology and early-stage detection is a powerful driver of the gastric cancer diagnostics industry, especially as public health systems seek to reduce long-term treatment costs.

The shift toward personalized medicine is significantly influencing the gastric cancer diagnostics industry. Biomarker-based tests and genomic profiling allow clinicians to tailor treatments to individual patient profiles, improving therapeutic outcomes. This precision approach relies on advanced diagnostic tools such as next-generation sequencing (NGS), immunohistochemistry, and companion diagnostics. As targeted therapies become more prevalent, the need for molecular diagnostics to identify HER2, PD-L1, MSI, and other biomarkers in gastric cancer grows. Personalized medicine improves survival and enhances the cost-effectiveness of care, encouraging both healthcare providers and payers to adopt more advanced diagnostic platforms. For example, in metastatic biliary tract cancers, younger individuals tended to have a better prognosis than older patients, because their tumors were more likely to contain actionable genetic alterations that made them suitable candidates for personalized treatments.

Biomarkers can detect earlier molecular and genetic changes associated with cancer development, which is crucial for improving patient outcomes. Biomarkers, especially those found in blood or other body fluids, provide non-invasive or minimally invasive options, reducing patient discomfort compared to endoscopy or biopsy. They also allow for real-time monitoring of disease progression and treatment response, facilitating personalized medicine. Moreover, biomarkers can help differentiate between benign and malignant lesions with higher sensitivity and specificity, overcoming limitations of imaging such as low resolution or operator dependency. Hence, some emerging trends in biomarkers for gastric cancer diagnostics are listed below.

Global Gastric Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global gastric cancer diagnostics market report based on product, disease type, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Reagents & Consumables
  • Instruments
  • Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Adenocarcinoma
  • Gastric lymphoma
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Diagnostic Imaging
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease Type
    • 1.2.3. End use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Disease type outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Gastric Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Gastric Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Gastric Cancer Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Gastric Cancer Diagnostics Market: Product Movement Analysis
  • 4.4. Gastric Cancer Diagnostics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.5. Gastric Cancer Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Reagents & consumables
    • 4.6.1. Reagents & consumables Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Instruments
    • 4.7.1. Instruments Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Gastric Cancer Diagnostics Market: Disease Type Estimates & Trend Analysis

  • 5.1. Disease Type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Gastric Cancer Diagnostics Market by Disease Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Adenocarcinoma
    • 5.5.1. Adenocarcinoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Gastric lymphoma
    • 5.6.1. Gastric Lymphoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Gastric Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Gastric Cancer Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Diagnostic Imaging
    • 6.7.1. Diagnostic Imaging Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Gastric Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts, Trend Analysis, 2021 to 2033:
  • 7.5. North America
    • 7.5.1. North America: SWOT Analysis
    • 7.5.2. U.S.
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/Reimbursement
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/Reimbursement
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/Reimbursement
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. Europe: SWOT Analysis
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/Reimbursement
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. Germany
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/Reimbursement
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/Reimbursement
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/Reimbursement
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Spain
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/Reimbursement
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Norway
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/Reimbursement
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Sweden
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/Reimbursement
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.9. Denmark
      • 7.6.9.1. Key country dynamics
      • 7.6.9.2. Regulatory framework/Reimbursement
      • 7.6.9.3. Competitive scenario
      • 7.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Asia Pacific: SWOT Analysis
    • 7.7.2. Japan
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/Reimbursement
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. China
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/Reimbursement
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. India
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/Reimbursement
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/Reimbursement
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/Reimbursement
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.7. Thailand
      • 7.7.7.1. Key country dynamics
      • 7.7.7.2. Regulatory framework/Reimbursement
      • 7.7.7.3. Competitive scenario
      • 7.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Latin America: SWOT Analysis
    • 7.8.2. Brazil
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/Reimbursement
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/Reimbursement
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. MEA: SWOT Analysis
    • 7.9.2. South Africa
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/Reimbursement
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/Reimbursement
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/Reimbursement
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key country dynamics
      • 7.9.5.2. Regulatory framework
      • 7.9.5.3. Competitive scenario
      • 7.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. MiRXES Pte Ltd.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Agilent Technologies Inc
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Endofotonics Pte Ltd
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Bio-Rad Laboratories, Inc
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Hipro Biotechnology Co., Ltd
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Exact Sciences Corporation
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. QIAGEN
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Fulgent Genetics.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. F. Hoffmann-La Roche Ltd
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Abbott
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Gastric Cancer Diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 4 North America Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 5 North America Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 6 U.S Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 7 U.S Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 8 U.S Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Canada Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 10 Canada Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 11 Canada Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 12 Mexico Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 13 Mexico Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Europe Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 16 Europe Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 17 Europe Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 18 UK Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 19 UK Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 20 UK Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 21 Germany Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 22 Germany Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 23 Germany Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 24 France Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 25 France Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 26 France Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 27 Italy Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 28 Italy Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 29 Italy Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 30 Spain Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 31 Spain Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 32 Spain Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 33 Denmark Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 34 Denmark Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 35 Denmark Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 36 Sweden Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 37 Sweden Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 38 Sweden Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 39 Norway Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 40 Norway Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 41 Norway Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 42 Asia Pacific Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 45 Japan Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 46 Japan Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 47 Japan Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 48 China Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 49 China Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 50 China Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 51 India Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 52 India Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 53 India Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 54 Australia Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 55 Australia Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 56 Australia Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 57 South Korea Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 58 South Korea Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 59 South Korea Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 60 Thailand Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 61 Thailand Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 62 Thailand Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 63 Latin America Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 64 Latin America Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 65 Latin America Gastric Cancer Diagnostics market, by end use 2021 - 2033 (USD Million)
  • Table 66 Brazil Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 67 Brazil Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 68 Brazil Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 69 Argentina Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 70 Argentina Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 71 Argentina Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 72 MEA Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 73 MEA Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 74 MEA Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 75 South Africa Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 76 South Africa Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 77 South Africa Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 78 Saudi Arabia Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 79 Saudi Arabia Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 80 Saudi Arabia Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 81 UAE Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 82 UAE Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 83 UAE Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 84 Kuwait Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 85 Kuwait Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 86 Kuwait Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Gastric Cancer Diagnostics market: market outlook
  • Fig. 14 Gastric Cancer Diagnostics Competitive Insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Gastric Cancer Diagnostics Market Driver Impact
  • Fig. 20 Gastric Cancer Diagnostics Market Restraint Impact
  • Fig. 21 Gastric Cancer Diagnostics Market Strategic Initiatives Analysis
  • Fig. 22 Gastric Cancer Diagnostics market: Product movement analysis
  • Fig. 23 Gastric Cancer Diagnostics market: Product outlook and key takeaways
  • Fig. 24 Reagents & consumables market estimates and forecasts, 2021 - 2033
  • Fig. 25 Instruments market estimates and forecasts,2021 - 2033
  • Fig. 26 Gastric Cancer Diagnostics Market: Disease Type Movement Analysis
  • Fig. 27 Gastric Cancer Diagnostics market: Disease type outlook and key takeaways
  • Fig. 28 Adenocarcinoma market estimates and forecasts, 2021 - 2033
  • Fig. 29 Gastric lymphoma market estimates and forecasts, 2021 - 2033
  • Fig. 30 Other market estimates and forecasts, 2021 - 2033
  • Fig. 31 Gastric Cancer Diagnostics Market: End use movement analysis
  • Fig. 32 Gastric Cancer Diagnostics market: End use outlook and key takeaways
  • Fig. 33 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 34 Diagnostic Laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 35 Diagnostic Imaging market estimates and forecasts, 2021 - 2033
  • Fig. 36 Global Gastric Cancer Diagnostics market: Regional movement analysis
  • Fig. 37 Global Gastric Cancer Diagnostics market: Regional outlook and key takeaways
  • Fig. 38 Global Gastric Cancer Diagnostics market share and leading players
  • Fig. 39 North America market share and leading players
  • Fig. 40 Europe market share and leading players
  • Fig. 41 Asia Pacific market share and leading players
  • Fig. 42 Latin America market share and leading players
  • Fig. 43 Middle East & Africa market share and leading players
  • Fig. 44 North America, by country
  • Fig. 45 North America
  • Fig. 46 North America market estimates and forecasts, 2021 - 2033
  • Fig. 47 U.S.
  • Fig. 48 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 49 Canada
  • Fig. 50 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 51 Mexico
  • Fig. 52 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 53 Europe
  • Fig. 54 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 55 UK
  • Fig. 56 UK market estimates and forecasts, 2021 - 2033
  • Fig. 57 Germany
  • Fig. 58 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 59 France
  • Fig. 60 France market estimates and forecasts, 2021 - 2033
  • Fig. 61 Italy
  • Fig. 62 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 63 Spain
  • Fig. 64 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 65 Denmark
  • Fig. 66 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 67 Sweden
  • Fig. 68 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 69 Norway
  • Fig. 70 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 71 Asia Pacific
  • Fig. 72 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 73 China
  • Fig. 74 China market estimates and forecasts, 2021 - 2033
  • Fig. 75 Japan
  • Fig. 76 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 77 India
  • Fig. 78 India market estimates and forecasts, 2021 - 2033
  • Fig. 79 Thailand
  • Fig. 80 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 81 South Korea
  • Fig. 82 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 83 Australia
  • Fig. 84 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 85 Latin America
  • Fig. 86 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 87 Brazil
  • Fig. 88 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 89 Argentina
  • Fig. 90 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 91 Middle East and Africa
  • Fig. 92 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 93 South Africa
  • Fig. 94 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 95 Saudi Arabia
  • Fig. 96 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 97 UAE
  • Fig. 98 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 99 Kuwait
  • Fig. 100 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 101 Market share of key market players- Gastric Cancer Diagnostics market